BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2020 Earnings Conference Call May 6, 2020 8:30 AM ET Company Participants John Bluth - Senior Vice President, Investor Relations and Corporate Communications Jon Stonehouse - President and Chief Executive Officer Charlie Gayer - Chief Commercial Officer Megan Sniecinski - Chief Business Officer William Sheridan - Chief Medical Officer Anthony Doyle - Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Gena Wang - Barclays PLC Tyler Van ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ Form 10-K ________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 000-23186 ________________________ BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2019 Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 62-1413174 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 4505 Emperor Blvd., Suite 200 Durham, North Carolina ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2019 Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 62-1413174 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2019 Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 62-1413174 (State of other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 4505 Emperor Blvd., Suite 200 Durham, North Carolina 2770 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ ________________________ Form 10-K ________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to . Commission File Number 000-23186 BIOCRYST PHARMACEUTICALS, INC. (Exact name of registrant as ...